Sarepta Therapeutics (SRPT) Operating Leases (2019 - 2026)

Sarepta Therapeutics has reported Operating Leases for 8 years, with the latest figure at $198.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 3.39% year-over-year to $198.5 million; the trailing twelve-month figure through Mar 2026 stood at $198.5 million (down 3.39% YoY), and the FY2025 full-year result was $199.4 million, up 3.59% from the prior year.
• Operating Leases for Q1 2026 stood at $198.5 million, roughly flat from $199.4 million in the prior quarter.
• The five-year high for Operating Leases was $215.0 million in Q3 2025, with the low at $35.2 million in Q3 2022.
• Average Operating Leases over 5 years is $135.8 million, with a median of $141.0 million recorded in 2023.
• Year-over-year, Operating Leases slumped 44.46% in 2022 and jumped 282.5% in 2023.
• Tracing SRPT's Operating Leases over 5 years: stood at $57.6 million in 2022, then surged by 144.82% to $141.0 million in 2023, then surged by 36.54% to $192.5 million in 2024, then advanced by 3.59% to $199.4 million in 2025, then slipped by 0.44% to $198.5 million in 2026.
• The last three Operating Leases figures came in at $198.5 million (Q1 2026), $199.4 million (Q4 2025), and $215.0 million (Q3 2025), per Business Quant data.

Peer Comparison